
-
SFWJ / Medcana Announces Strategic Expansion Into Australia With Acquisition of Cannabis Import and Distribution Licenses
-
Arsenal's Havertz could return for Champions League final
-
US officials split on Ukraine truce prospects
-
Client brain-dead after Paris cryotherapy session goes wrong
-
Flick demands answers from La Liga for 'joke' schedule
-
'Maddest game' sums up Man Utd career for Maguire
-
Trial opens for students, journalists over Istanbul protests
-
Gaza rescuers say Israeli strikes kill 24 after Hamas rejects truce proposal
-
'Really stuck': Ukraine's EU accession drive stumbles
-
'Not the time to discuss future', says Alonso amid Real Madrid links
-
74 killed in deadliest US attack on Yemen, Huthis say
-
Southgate's ex-assistant Holland fired by Japan's Yokohama
-
Vance meets Meloni in Rome before Easter at the Vatican
-
Ryan Gosling to star in new 'Star Wars' film
-
Hamas calls for pressure to end Israel's aid block on Gaza
-
Russia says Ukraine energy truce over, US mulls peace talks exit
-
58 killed in deadliest US strike on Yemen, Huthis say
-
Museums rethink how the Holocaust should be shown
-
Three dead after deadly spring storm wreaks havoc in the Alps
-
No need for big changes at Liverpool, says Slot
-
Bloody Philippine passion play sees final performance of veteran 'Jesus'
-
New US envoy prays, delivers Trump 'peace' message at Western Wall
-
Postecoglou sticking around 'a little longer' as Spurs show fight in Frankfurt
-
US threatens to withdraw from Ukraine talks if no progress
-
Tears and defiance in Sumy as Russia batters Ukraine border city
-
Russia rains missiles on Ukraine as US mulls ending truce efforts
-
Tokyo leads gains in most Asian markets on trade deal hopes
-
Two missing after deadly spring snowstorm wreaks havoc in the Alps
-
'War has taken everything': AFP reporter returns home to Khartoum
-
US strikes on Yemen fuel port kill 38, Huthis say
-
Slegers targets Lyon scalp in pursuit of Arsenal European glory
-
'Defend ourselves': Refugee girls in Kenya find strength in taekwondo
-
China's manufacturing backbone feels Trump trade war pinch
-
Sri Lankans throng to Kandy for rare display of Buddhist relic
-
Chinese vent anger at Trump's trade war with memes, mockery
-
Heartbroken Brits abandon pets as living costs bite
-
Mongolian LGBTQ youth fight for recognition through music, comedy
-
Cash crunch leaves Syrians queueing for hours to collect salaries
-
Lyon left to regroup for Champions League bid after painful European exit
-
Unravelling Real Madrid face Athletic Bilbao Liga test
-
Napoli disturbing buoyant Inter's peace in Serie A Easter bonanza
-
Disappointed Dortmund chase consistency with Europe at stake
-
Asian markets mixed as traders track tariff talks
-
Yan and Buhai share lead at LA Championship
-
Under fire at debate, Canada PM Carney tries to focus on Trump
-
Liverpool poised for Premier League coronation, Leicester, Ipswich for relegation
-
India's elephant warning system tackles deadly conflict
-
US senator meets wrongfully deported Salvadoran migrant
-
Gustavo Dudamel: the superstar conductor building bridges to pop
-
Japan rice prices soar as core inflation accelerates

PetVivo Holdings, Inc. Announces Participation in The Microcap Conference 2025
PetVivo Holdings, Inc. (OTCQB:PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
John Lai, Chief Executive Officer of PetVivo Holdings, Inc. will provide a Company overview as well as discuss its lead product, SPRYNG™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.
The 2025 event will feature:
Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.
Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.
Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.
Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB:PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company's commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email [email protected] or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company's Investor Relations website, in addition to following the company's press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
SOURCE: PetVivo Holdings, Inc.
P.Stevenson--AMWN